



FIG. 1

FIG. 2

Fibronectin (43kDa fragment)



Fibronectin (72kDa fragment)





FIG. 3 Fibronectin final concentration (29kDa fragment)



C-terminal

FIG. 4 N-terminal

29kD	43kD
------	------


Fibronectin structure

72kD

Fragments	Binding molecules
29 kD	Actin, Heparin, Fibrin, etc.
43 kD	Collagen (Gelatin)

29 kD	43 kD	72 kD
TF efficiency	○	○
Cross-contamination	none	some

FIG. 5






Fig. 7






FIG. 8



Fibronectin(+)



Fibronectin(-)




FIG. 9




FIG. 10



FIG. 11**FIG. 12**

FIG. 13




FIG. 13C




FIG. 14




FIG. 14C





FIG. 14D


Scheme for HEK293			
For HEK293			1.5mL micro-tube
DMEM (serum free)	9.5	uL	↓ ←DMEM
Plasmid DNA (1mg/mL)	1.5	uL	↓ ←Plasmid DNA
TransFast (1mg/mL)	9.0	uL	mix Incubate for 2-3 days
DMEM (serum free)	5.0	uL	↓ ←TransFast at 37°C in 5% CO ₂
Fibronectin (4mg/mL)	5.0	uL	mix completely and incubate for 15 min at RT
Final volume	30.0	uL	↓ ←DMEM
			↓ ←Fibronectin
			mix completely
			↓
			ready to print
Scheme for HeLa, NIH3T3-3, and HepG2			
For HeLa, NIH3T3-3, HepG2			1.5mL micro-tube
DMEM (serum free)	14.5	uL	↓ ←DMEM
Plasmid DNA (1mg/mL)	1.5	uL	↓ ←Plasmid DNA
Lipofectamine2000	4.5	uL	mix
DMEM (serum free)	5.0	uL	↓ ←Lipofectamine2000
Fibronectin (4mg/mL)	5.0	uL	mix completely and incubate for 15 min at RT
Final volume	30.0	uL	↓ ←DMEM
			↓ ←Fibronectin
			mix completely
			↓
			ready to print
Scheme for hMSCs			
For hMSCs			1.5mL micro-tube
	N/P=5	N/P=10	N/P=20
DMEM (serum free)	12.75	12.0	10.5 uL
Plasmid DNA (1mg/mL)	1.5	1.5	1.5 uL
JetPEI (x4) conc.	0.75	1.5	3.0 uL
Fibronectin (4mg/mL)	5.0	5.0	5.0 uL
Final volume	20.0	20.0	20.0 uL
			↓ ←DMEM
			↓ ←Plasmid DNA
			mix
			↓ ←jetPEI
			mix completely and incubate for 15 min at RT
			↓ ←Fibronectin
			mix completely
			↓
			ready to print

FIG. 15

A




B





B



A

FIG. 16

FIG. 16C

Number of adherent cells		Time(min)					
		0	5	10	15	20	30
APS		235	220	202	157	170	162
APS+gelatin		212	206	184	145	156	183
APS+fibronectin		229	198	183	132	100	85
APS+pronectin L		257	170	126	94	71	47
PLL		231	221	205	182	168	159
PLL+gelatin		218	208	186	151	146	156
PLL+fibronectin		225	174	162	129	98	79
PLL+pronectin L		214	151	132	90	76	50
MAS		231	222	216	182	176	169
MAS+gelatin		224	198	182	163	159	162
MAS+fibronectin		218	182	169	143	112	86
MAS+pronectin L		220	176	152	124	101	66
No coating		226	216	208	192	183	164

Cell adhesion rate (proportion of adherent cells (%))

	Time(min)					
	0	5	10	15	20	30
APS	0	6.382979	14.04255	33.19149	27.65957	31.06383
APS+gelatin	0	2.830189	13.20755	31.60377	26.41509	13.67925
APS+fibronectin	0	13.53712	20.08734	42.35808	56.33188	62.8821
APS+pronectin L	0	33.85214	50.97276	63.42412	72.37354	81.71206
PLL	0	4.329004	11.25541	29.87013	27.27273	31.16883
PLL+gelatin	0	4.587156	14.6789	30.73394	33.02752	28.44037
PLL+fibronectin	0	22.66667	28	42.66667	56.44444	64.88889
PLL+pronectin L	0	29.43925	38.31776	57.94393	64.48598	76.63551
MAS	0	3.896104	6.493506	21.21212	23.80952	26.83983
MAS+gelatin	0	11.60714	18.75	27.23214	29.01786	27.67857
MAS+fibronectin	0	16.51376	22.47706	34.40367	48.62385	60.55046
MAS+pronectin L	0	20	30.90909	43.63636	54.09091	70
No coating	0	4.424779	7.964602	15.04425	19.02655	27.43363





FIG. 16D









FIG. 17

FIG. 18A



	0-31.5 hr	17.5-31.5 hr	0-17.5 hr
A	+	+	+
B	+	+	-

FIG. 18B



	0-31.5 hr	17.5-31.5 hr	0-17.5 hr
NFAT	+	+	+
ERE	+	-	-
NFAT/ERE	+	+	-

FIG. 19




FIG. 20




FIG. 21

No induction of differentiation	0-31.5	0-17.5	17.5-31.5
Extraction number=1	5.882353	5.882353	0
Extraction number=2	0	0	0
Extraction number=3	0	0	0
Extraction number=5	0	0	0
Extraction number=8	0	0	0
Extraction number=16	0	0	0
Extraction number=17	0	0	0





FIG. 22

FIG. 23






FIG. 24

Construction of transcription factor reporter

Vector	Pathway	Transcription factor	Cis-acting enhancer element
pNFkB-d2FGFP	IKK/NFkB	NFkB	kB
pAP1-d2FGFP	SAPK/JNK	c-Jun, c-Fos	AP1
pSRF-d2FGFP	MAPK/JNK, MAPK/FRK	Flk-1, STAT, TCF, SRF	SRF
pGRF-d2FGFP	Glicocorticoidé (HXP90 mediation)	GR	GRF
pCRE-d2FGFP	PKA/CRFB, JNK/p38 PKA	ATF2/CRFB	CRE
pMpc-TA-d2FGFP, pMYC-d2FGFP	Cell cycle	c-myc	F-box
pHSF-d2FGFP	HSF	HSF	HSF
pNFAT-d2FGFP	NFAT/Calcineurin/PKC	NFAT	NFAT
pAP1(PMA)-TA-d2FGFP	PKC		AP1(PMA)
pRB-TA-d2FGFP	Cell cycle		Rb
pF2F-TA-d2FGFP	Cell cycle		F2F
pp53-TA-d2FGFP	Cell cycle apoptosis		P53
pGAN-TA-d2FGFP	JAK/STAT	STAT1/STAT1	GAS
pISRF-TA-d2FGFP	JAK/STAT	STAT2/STAT1	ISRF
pSTAT3-TA-d2FGFP	JAK/STAT	STAT3/STAT3	STAT3
pFRF-TA-d2FGFP	Estrogen receptor		FRF
pRARF-TA-d2FGFP	Retinoic acid		RARF
pTRF-TA-d2FGFP	Thyroid receptor		TRF




FIG. 25





FIG. 26

FIG. 27






FIG. 28

Fig. 29






FIG. 30





Fig. 32






Fig. 33




Fig. 35





Fig. 36
Format of Experiments



570 grid slide

Fig. 37




Fig. 38A Results (HeLa Cell strain)

Change of Culture medium (10%FBS → Serum Free)




Fig. 38C




Fig. 39-1

Fig. 39-2




Fig. 39-3




Fig. 39-4

CRE




Fig. 39-5

E2F





Fig. 39-6

EGFP-N1

52/110

AI012






Fig. 39-7

Fig. 39-8




Fig. 39-9

API(FDMA)




Fig. 39-10

CRE




Fig. 39-11

E2F




Fig. 39-12

ERE




Fig. 39-13

GAS




Fig. 39-14

GRE




Fig. 39-15

HSE



Fig. 39-16

ISRE




Fig. 39-17

none




Fig. 39-18

ERIE




Fig: 39-19

GAS

65/110

AI012




Fig. 39-20

GRE




Fig. 39-21

HSE




Fig. 39-22

ISRE




Fig. 39-23

Myc




Fig. 39-24

NFAT




Fig. 39-25

NFKB




Fig. 39-26

RARE




Fig. 39-27

Rb




Fig. 39-28

none




Fig. 39-29

Myo.




Fig. 39-3.0

NFAT

76/110

AI012




Fig. 39-31

NFkB




Fig. 39-32

RARE




Fig. 39-33

Rb




Fig. 39-34

STAT3

80/110

AI012




Fig. 39-35

SRE

81/110

AI012




Fig. 39-36

TRE







Fig. 39-37

p53





none






Fig. 39-41

SRE




Fig. 39-42

TRE

88/110

AI012





Fig. 39-43

p53






Fig. 39-45

CREB-EGFP




Fig. 39-46

β B-EGFP




Fig. 39-47

pp53-EGFP





Fig. 39-48

none



none




Fig. 39-50

none




Fig: 39-51

CREB-EGFP




Fig: 39-52

JKB-EGFP




Fig. 3.9-5.3

pp53-EGFP




Fig. 39-54

none




Fig. 39-55

none






Fig. 40.









Fig. 42

Fig. 43






Fig. 44




Fig. 45

Fig. 46




Fig. 47




Fig. 48

Change in Stock Price

